MétaCan
Menu
Back to cohort
Record W4404152920 · doi:10.1017/cjn.2024.285

Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis

2024· article· en· W4404152920 on OpenAlexaffvenueabout
Ioana Medrea, Paul E. Cooper, Claire H. Sandoe, Farnaz Amoozegar, Mohammed Hussain, Ana C. Bradi, Jessica Dawe, Meagan Guay, Francois Perreault, Stuart Reid, Candice Todd, Becky Skidmore, Suzanne Christie

Bibliographic record

VenueCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2024
Typearticle
Languageen
FieldMedicine
TopicMigraine and Headache Studies
Canadian institutionsQueen's UniversityUniversité de MontréalMcMaster UniversitySt. Joseph’s Healthcare HamiltonDalhousie UniversityHealth Sciences CentreOttawa HospitalAlberta Hospital EdmontonUniversity of AlbertaUniversity of OttawaSouth Health CampusKingston General HospitalSt Joseph's Health CareUniversity of CalgaryWomen's College HospitalLondon Health Sciences CentreAlberta Health ServicesWestern UniversityUniversity of Toronto
Fundersnot available
KeywordsGuidelineMigraineMedicineMeta-analysisSystematic reviewFamily medicineMEDLINEPsychiatryPolitical scienceInternal medicinePathology

Abstract

fetched live from OpenAlex

OBJECTIVE: We have updated the migraine prevention guideline of the Canadian Headache Society from 2012, as there are new therapies available, and additionally, we have provided guidelines for the prevention of chronic migraine, which was not addressed in the previous iteration. METHODS: We undertook a systematic review to identify new studies since the last guideline. For studies identified, we performed data extraction and subsequent meta-analyses where possible. We composed a summary of the evidence found and undertook a modified Delphi recommendation process. We provide recommendations for treatments identified and additionally expert guidance on the use of the treatments available in important clinical situations. RESULTS: We identified 61 studies that were included in this evidence update and identified 16 therapies we focused on. The anti-calcitonin gene-related peptide (CGRP) agents were approved by Health Canada between 2018 and 2024 and provide additional options for episodic and chronic migraine prevention. We also summarize evidence for the use of propranolol, topiramate and onabotulinumtoxinA in addition to anti-CGRP agents as treatments for chronic migraine. We have downgraded topiramate to a weak recommendation for use and gabapentin to a weak recommendation against its use in episodic migraine. We have weakly recommended the use of memantine, levetiracetam, enalapril and melatonin in episodic migraine. CONCLUSION: Based on the evidence synthesis, we provide updated recommendations for the prevention of episodic and chronic migraine utilizing treatments available in Canada. We additionally provided expert guidance on their use in clinical situations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.043
metaresearch head score (Gemma)0.155
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.889
Threshold uncertainty score0.225

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0430.155
Meta-epidemiology (narrow)0.0030.003
Meta-epidemiology (broad)0.0130.026
Bibliometrics0.0220.016
Science and technology studies0.0020.001
Scholarly communication0.0050.004
Open science0.0080.004
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0160.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.076
GPT teacher head0.335
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2024
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Journal of Neurological Sciences / Journal Canadien des Sciences NeurologiquesSame topicMigraine and Headache StudiesFrench-language works237,207